

Date: Wednesday, 14th February 2024

Our Ref: MB/CM FOI 6172

Sid Watkins Building Lower Lane Fazakerley Liverpool L9 7BB Tel: 01515253611

Fax: 01515295500 Direct Line: 01515563038

Re: Freedom of Information Request FOI 6172

We are writing in response to your request submitted under the Freedom of Information Act, received in this office on 14th February 2024.

Your request was as follows:

I am analysing the treatment of lung cancer and would greatly appreciate if you could answer the following question:


Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- •□ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
- □ Amivantamab
- □Atezolizumab Monotherapy
- □ Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
- □ Dabrafenib + Trametinib
- □ Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
- □ Durvalumab
- □ Gemcitabine
- Nitedanib + Docetaxel
- ■Nivolumab
- □ Osimertinib
- □ Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
- □ Paclitaxel
- □Pembrolizumab Monotherapy
- •□Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
- □ Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
- □ Pemetrexed + Platinum (Carboplatin/Cisplatin)
- •□RET Inhibitors (Pralsetinib, Selpercatinib)
- •□Sotorasib
- □ Tepotinib









- □ Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
- Other active systemic anti-cancer therapy
- □ Palliative care only

The Walton Centre NHS Foundation Trust is a Specialist Neuroscience Tertiary Care Centre; we do not provide services for lung cancer. Therefore, we cannot provide this information.

Please see our response above in blue.

Re-Use of Public Sector Information

All information supplied by the Trust in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2005, Statutory Instrument 2005 No. 1515 which came into effect on 1st July 2005.

Under the terms of the Regulations, the Trust will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however the Trust reserves the right, in certain circumstances, to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information can be found at www.opsi.gov.uk where a sample license terms and fees can be found with guidance on copyright and publishing notes and a Guide to Best Practice and regulated advice and case studies, at www.opsi.gov.uk/advice/psi-regulations/index.htm

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to the Freedom of Information Office at the address above.

Please remember to quote the reference number, FOI 6172 in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted by:

Post: Information Commissioners Office, Wycliffe House, Water Lane, Wilmslow, CHeshire, SK9 5AF.

Online: https://ico.org.uk/make-a-complaint/foi-and-eir-complaints/

Telephone: 0303 123 1113

Yours sincerely Mike Burns

Mr. Mike Burns, Executive Lead for Freedom of Information



